BRPI0410867A - composto, medicamento, inibidor de apresentação de antìgeno, agente imunossupressor, inibidores de proliferação de linfócitos, e de crescimento e maturação de células, agente terapêutico ou preventivo, indutor de toleráncia imunológica, e, droga anti-cáncer - Google Patents

composto, medicamento, inibidor de apresentação de antìgeno, agente imunossupressor, inibidores de proliferação de linfócitos, e de crescimento e maturação de células, agente terapêutico ou preventivo, indutor de toleráncia imunológica, e, droga anti-cáncer

Info

Publication number
BRPI0410867A
BRPI0410867A BRPI0410867-1A BRPI0410867A BRPI0410867A BR PI0410867 A BRPI0410867 A BR PI0410867A BR PI0410867 A BRPI0410867 A BR PI0410867A BR PI0410867 A BRPI0410867 A BR PI0410867A
Authority
BR
Brazil
Prior art keywords
drug
agent
therapeutic
inhibitor
compound
Prior art date
Application number
BRPI0410867-1A
Other languages
English (en)
Inventor
Akira Masuda
Yoshitaka Satoh
Yuji Akiyama
Kan Saiga
Eriko Toyoda
Original Assignee
Nippon Kayaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Kk filed Critical Nippon Kayaku Kk
Publication of BRPI0410867A publication Critical patent/BRPI0410867A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTO, MEDICAMENTO, INIBIDOR DE APRESENTAçãO DE ANTìGENO, AGENTE IMUNOSSUPRESSOR, INIBIDORES DE PROLIFERAçãO DE LINFóCITOS, E DE CRESCIMENTO E MATURAçãO DE CéLULAS, AGENTE TERAPêUTICO OU PREVENTIVO, INDUTOR DE TOLERáNCIA IMUNOLóGICA, E, DROGA ANTI-CáNCER". Derivado de ¢1,2,4!triazolo¢1,5-a!pirimidina inédito da fórmula geral (1): (1) prodroga do mesmo ou um sal farmaceuticamente aceitável do mesmo, que apresenta uma atividade inibidora de apresentação de antígeno e é útil como um agente preventivo e/ou terapêutico para rejeição imunológica e/ou reação do enxerto contra hospedeiro em transplante de órgão/medula óssea, doença autoimune, doença alérgica e/ou doença inflamatória e também útil como uma droga anti-câncer ou como um indutor de tolerância imunológica para órgão transplantado/medula óssea transplantada.
BRPI0410867-1A 2003-06-03 2004-06-02 composto, medicamento, inibidor de apresentação de antìgeno, agente imunossupressor, inibidores de proliferação de linfócitos, e de crescimento e maturação de células, agente terapêutico ou preventivo, indutor de toleráncia imunológica, e, droga anti-cáncer BRPI0410867A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003157663 2003-06-03
PCT/JP2004/007623 WO2004108729A1 (ja) 2003-06-03 2004-06-02 ［１，２，４］トリアゾロ［１，５−a］ピリミジン−２−イルウレア誘導体とその用途

Publications (1)

Publication Number Publication Date
BRPI0410867A true BRPI0410867A (pt) 2006-07-04

Family

ID=33508397

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410867-1A BRPI0410867A (pt) 2003-06-03 2004-06-02 composto, medicamento, inibidor de apresentação de antìgeno, agente imunossupressor, inibidores de proliferação de linfócitos, e de crescimento e maturação de células, agente terapêutico ou preventivo, indutor de toleráncia imunológica, e, droga anti-cáncer

Country Status (14)

Country Link
US (1) US7598244B2 (pt)
EP (1) EP1630165B1 (pt)
JP (1) JP4698419B2 (pt)
KR (1) KR101097479B1 (pt)
CN (1) CN1809570B (pt)
AT (1) ATE462705T1 (pt)
AU (1) AU2004245351B2 (pt)
BR (1) BRPI0410867A (pt)
CA (1) CA2526211C (pt)
DE (1) DE602004026298D1 (pt)
RU (1) RU2348636C2 (pt)
TW (1) TWI334868B (pt)
WO (1) WO2004108729A1 (pt)
ZA (1) ZA200509436B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005104895A (ja) * 2003-09-30 2005-04-21 Nippon Kayaku Co Ltd 光学活性なアミノアルコール化合物の製造法
JP4606015B2 (ja) * 2003-11-25 2011-01-05 日本化薬株式会社 ［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体の新規医薬用途
AU2005263592A1 (en) * 2004-07-20 2006-01-26 Siena Biotech S.P.A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
AU2007219509A1 (en) * 2006-01-18 2007-09-07 Siena Biotech S.P.A Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
CN101420963B (zh) * 2006-02-09 2012-09-05 安佐制药股份有限公司 用于治疗乳腺癌、结肠直肠癌、胰腺癌、卵巢癌和肺癌的7-乙基-10-羟基喜树碱的多臂聚合轭合物
GB0612630D0 (en) * 2006-06-26 2006-08-02 Novartis Ag Organic compounds
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
KR100844125B1 (ko) * 2007-03-23 2008-07-04 한국화학연구원 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
EP2444403A1 (en) * 2008-04-18 2012-04-25 Shionogi Co., Ltd. Heterocyclic compound having inhibitory activity on PI3K
US20130052734A1 (en) 2010-02-23 2013-02-28 National University Corporation Hokkaido University Method for preparing regulatory dendritic cells
BR112014005669A2 (pt) * 2011-09-14 2017-04-04 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
KR102116107B1 (ko) 2013-12-30 2020-05-28 삼성디스플레이 주식회사 표시 장치
USRE49816E1 (en) 2014-01-10 2024-01-30 Cornell University Dipeptides as inhibitors of human immunoproteasomes
JP6758282B2 (ja) * 2014-08-18 2020-09-23 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ ヒト免疫プロテアソーム阻害剤としてのジペプチド模倣薬
CN108351169B (zh) 2015-10-15 2022-01-28 康奈尔大学 蛋白酶体抑制剂及其用途
CN107522641B (zh) * 2016-06-22 2020-05-05 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
EP3476829B1 (en) 2016-06-22 2021-12-15 Fudan University Biaryl urea derivative or salt thereof, and manufacturing and application of same
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
EP3818053B1 (en) * 2018-07-05 2023-03-29 Sanford Burnham Prebys Medical Discovery Institute Fused ring compound having urea structure

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654343A (en) * 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
JPH01270051A (ja) * 1988-04-22 1989-10-27 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
US5880066A (en) * 1990-12-11 1999-03-09 Monsanto Company Safened herbicidal sulfonamide compositions
US5484760A (en) 1990-12-31 1996-01-16 Monsanto Company Herbicide antidotes as safeners for reducing phytotoxicity resulting from synergistic interaction between herbicides and other pesticides
JPH10206995A (ja) * 1997-01-21 1998-08-07 Konica Corp ハロゲン化銀写真感光材料
WO2001030778A1 (en) 1999-10-27 2001-05-03 Novartis Ag Thiazole and imidazo [4,5-b] pyridine compounds and their pharmaceutical use
JP2001322933A (ja) * 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
WO2002020495A2 (en) * 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6737085B2 (en) * 2000-11-01 2004-05-18 Tokiwa Phytochemical Co., Ltd. Apocynum venetum extract for use as antidepressant

Also Published As

Publication number Publication date
WO2004108729A1 (ja) 2004-12-16
KR20060026033A (ko) 2006-03-22
AU2004245351A1 (en) 2004-12-16
CA2526211A1 (en) 2004-12-16
AU2004245351B2 (en) 2009-04-02
ATE462705T1 (de) 2010-04-15
TW200508238A (en) 2005-03-01
EP1630165B1 (en) 2010-03-31
DE602004026298D1 (de) 2010-05-12
US7598244B2 (en) 2009-10-06
RU2348636C2 (ru) 2009-03-10
JP4698419B2 (ja) 2011-06-08
JPWO2004108729A1 (ja) 2006-07-20
TWI334868B (en) 2010-12-21
KR101097479B1 (ko) 2011-12-22
ZA200509436B (en) 2007-03-28
CN1809570B (zh) 2011-06-22
CA2526211C (en) 2011-12-20
CN1809570A (zh) 2006-07-26
EP1630165A1 (en) 2006-03-01
RU2005137706A (ru) 2006-06-10
EP1630165A4 (en) 2007-11-21
US20070010515A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
BRPI0410867A (pt) composto, medicamento, inibidor de apresentação de antìgeno, agente imunossupressor, inibidores de proliferação de linfócitos, e de crescimento e maturação de células, agente terapêutico ou preventivo, indutor de toleráncia imunológica, e, droga anti-cáncer
CY1117672T1 (el) Αναστολεις της ανθρωπινης δελτα φωσφατιδυλ-ινοσιτολ-3-κινασης
Zhao et al. Macrophage subpopulations and their impact on chronic allograft rejection versus graft acceptance in a mouse heart transplant model
DE602005016718D1 (de) Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
RU2220977C2 (ru) Гетероциклы в качестве ингибиторов адгезии лейкоцитов и vla-4-антагонистов
DE69920732D1 (de) Bicyclische stickstoffheteroaryl verbindungen
RU2006128788A (ru) Производные фенил[4-(3-фенил-1н-пиразол-4-ил)пиримидин-2-ил] амина в качестве igf-1r ингибиторов
MX337817B (es) Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
HUP0301114A2 (hu) Pirrolo[2,3-d]pirimidin vegyületek, mint immunoszuppresszív hatóanyagok, és ezeket tartalmazó gyógyszerkészítmények
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
ATE473980T1 (de) Triazolopyridazine als proteinkinase-inhibitoren
MX2007005644A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de cinasa.
DE60014130D1 (de) Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
AU2003297160A1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
RU94042922A (ru) Новые соединения, способы их получения, фармацевтическая композиция
EA200601850A1 (ru) 6,6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ
GEP20074213B (en) Novel inhibitors of kinases
HK1098742A1 (en) Substituted 1h-pyrrolo [3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon
BR0007447A (pt) 2-aril-3-(heteroaril)-imidazo[1,2-a]pirimidinas substituìdas, composições farmacêuticas e métodos
EA200501516A1 (ru) Производные 2,3,6-тризамещённого-4-пиримидона
BRPI0513888A (pt) composição medicinal, métodos para a profilaxia ou tratamento de uma doença autoimune, e para preparação da composição medicinal, uso de uma composição medicinal, procedimento de administração, e, agente terapêutico
BRPI0408423A (pt) composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação
RU2004130284A (ru) Антипаразитарные производные артемизинина (эндопероксиды)
WO2022061155A9 (en) Imidazopyridazine and imidazopyrazine compounds as inhibitors of cdk7
Mokrov et al. Design, Synthesis, and Study of Anxiolytic Activity of New Pyrrolo [1, 2-a] Pyrazine-Containing TSPO Ligands

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.